MedTrace Logo

Monthly Dosing of Atacicept in IgAN

NCT07020923 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Conditions

  • IgA Nephropathy (IgAN)
  • Berger Disease

Interventions

DRUG

Atacicept

Drug: Atacicept

Sponsors & Collaborators

  • Vera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Zeeshan Khawaja · Vice President, Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2026-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07020923 on ClinicalTrials.gov